Link Cell Therapies Launches to Transform Cancer Treatment
Link Cell Therapies, an innovative oncology cell therapy company, has officially announced its launch with a significant $60 million Series A financing round. This funding received backing from both new and existing investors, with Johnson & Johnson leading the charge through its corporate venture arm.
This impressive financial backing builds on an earlier achievement, bringing the total funding raised by Link Cell Therapies to $92 million across seed and Series A rounds. Among the participants in this funding round were notable investors like Samsara BioCapital and Sheatree Capital, along with others that have joined the mission of advancing oncological therapeutics.
Innovative Technologies Mark New Era
At the core of Link's strategic advancements are their proprietary logic-gating technologies. This innovative platform is designed for the safe and effective targeting of multiple antigens that co-exist on cancer cells while minimizing interference with normal tissues. This capability opens the door for next-generation CAR-T therapies specifically engineered for both solid and liquid tumors.
Co-founder Robbie Majzner expressed the importance of this technology while emphasizing the current challenges faced in treating solid tumors. He noted that traditional CAR-T therapies face limitations due to the overlap of targets in healthy tissues. By employing logic-gated CAR-T cell control, Link aims to deliver treatment that selectively targets tumor cells without affecting nearby healthy cells.
Financial Investment Underlines Growth Potential
The recent Series A financing round acts as a catalyst for Link Cell Therapies as it looks to further develop its groundbreaking approaches. Following the 2022 Seed Funding round, this influx of capital reflects growing confidence from investors regarding the company’s potential to bring impactful treatments to the market.
Abraham Bassan, a member of Link’s Board and a partner at Samsara BioCapital, expressed his enthusiasm about the progress Link has made. He believes that the unique technology cultivated by the Link team stands poised to significantly improve treatment outcomes for patients battling cancer.
Development Progress on Leading Programs
Link’s lead therapeutic program, known as LNK001, represents critical advancements in the pursuit of effective cancer treatment. This program, primarily targeting renal cell carcinoma, is preparing for an Investigational New Drug (IND) application and is aiming to begin Phase I clinical trials in the near future.
LNK001 is specifically designed to target two antigens that have high co-expression rates in most renal cell carcinomas. This targeted approach is designed to maximize efficacy against tumors while minimizing the risk of on-target, off-tumor toxicity commonly seen in earlier therapies aimed at individual antigens.
Future Aspirations for Expansion
Additionally, Link is making strides on other applications such as a forthcoming program aimed at treating colorectal cancer. The company anticipates reaching Development Candidate selection by next year and initiating human clinical studies shortly thereafter.
Link’s robust pipeline doesn’t stop there. The company is committed to developing multiple CAR-T therapy programs for various solid and liquid tumors, further enhancing its therapeutic offerings through internal development and strategic collaborations.
About Link Cell Therapies
Founded by Robbie Majzner and Crystal Mackall at Stanford University, Link Cell Therapies aims to innovate within the biotechnology landscape. Their approaches are designed to improve patient outcomes significantly by focusing on safe targeting techniques that mitigate risk to non-cancerous tissues. With a team comprised of expert scientists and advisors, Link is dedicated to pushing the boundaries of CAR-T technology.
About Samsara BioCapital
Samsara BioCapital, established to drive significant impact in biotechnology investments, plays a pivotal role in advancing companies focused on high unmet medical needs. Through strategic partnerships with pioneering management teams, Samsara aligns itself with ventures that aim to usher in transformative therapeutics.
Frequently Asked Questions
What is Link Cell Therapies focused on?
Link Cell Therapies specializes in developing innovative CAR-T therapies for both solid and liquid tumors using unique targeting technologies.
What recent financial milestones has Link Cell Therapies achieved?
The company secured $60 million in Series A funding, contributing to a total of $92 million raised across seed and Series A financings.
What is the significance of LNK001?
LNK001 is Link's lead program targeting renal cell carcinoma, designed for optimal tumor specificity and minimized side effects.
How does Link Cell Therapies' technology differ from traditional methods?
Link's technology allows for simultaneous targeting of multiple antigens on cancer cells, which helps avoid damage to healthy tissues—an improvement over traditional CAR-T methods.
What future developments can be expected from Link?
Link plans to expand its pipeline by developing additional CAR-T programs, such as targeted treatments for colorectal cancer and more, ensuring diverse therapeutic options.
